Wyeth Enters Manufacturing Agreement for Genentech's Herceptin
This article was originally published in The Pink Sheet Daily
Executive Summary
Bulk drug substance for Herceptin will be manufactured at Wyeth's Andover, Mass. facility. The companies should be familiar with this type of arrangement since Genentech signed a deal in 2002 to manufacture Wyeth/Amgen's Enbrel.
You may also be interested in...
Genentech Ends Enbrel Manufacturing Agreement; Amgen Says Supply Will Not Be Affected
Genentech will pay Amgen $30 mil. to cancel Enbrel manufacturing agreement, transitioning capacity in its South San Francisco manufacturing facility to Avastin. Genentech is ramping up manufacturing at other facilities as well.
Genentech Ends Enbrel Manufacturing Agreement; Amgen Says Supply Will Not Be Affected
Genentech will pay Amgen $30 mil. to cancel Enbrel manufacturing agreement, transitioning capacity in its South San Francisco manufacturing facility to Avastin. Genentech is ramping up manufacturing at other facilities as well.
Genentech Names Former Lonza Exec To Manufacturing VP Post
Markus Gemuend assumes the position of VP-manufacturing collaborations and contract manufacturing, overseeing the company’s manufacturing outsourcing strategies. Former ZLB Behring exec Timothy Moore recently joined Genentech as VP-corporate engineering.